BridgeBio Oncology Therapeutics Inc.
BBOT | NASDAQ
$4.63
-$0.03 (-0.64%)
Sep 22, 2026, 9:33 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a |
Operating Income | -145.82M | -80.86M | -64.77M | -3.52K | -43.36K |
Interest Income | 11.34M | 8.46M | 72K | n/a | n/a |
Pretax Income | -134.04M | -74.28M | -64.7M | -3.52K | -43.36K |
Net Income | -134.04M | -74.28M | -64.7M | -3.52K | -43.36K |
Selling & General & Admin | 24.62M | 7.76M | 8.49M | 3.52K | 43.36K |
Research & Development | 121.2M | 73.11M | 56.29M | n/a | n/a |
Other Expenses | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 145.82M | 80.86M | 64.77M | 3.52K | 43.36K |
Interest Expense | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 145.82M | 80.86M | 64.77M | 3.52K | 43.36K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 31.14M | 16.64M | 20.49M | 20.49M | 20.49M |
Shares Outstanding (Diluted) | 31.14M | 16.64M | 20.49M | 20.49M | 20.49M |
EPS (Basic) | -4.30 | 0.46 | -3.16 | n/a | 0 |
EPS (Diluted) | -4.30 | 0.46 | -3.16 | 0 | 0 |
EBITDA | -145.21M | -80.66M | -64.68M | -3.52K | -43.36K |
EBIT | -145.82M | -80.86M | -64.77M | -3.52K | -43.36K |
Depreciation & Amortization | 610K | 208K | 92K | 3.52K | 74.33K |
Add to Watchlist
Select watchlists to add or remove BBOT